Antares Pharma Signs EasyTec(TM) ODT Agreement.

Provides Opportunity for Product Life Cycle Planning

EWING, N.J. -- Antares Pharma, Inc. (Amex:AIS) announced the signing of a feasibility and development agreement with an unnamed multi-national pharmaceutical partner for an opioid analgesic to be delivered using Antares' proprietary EasyTec[TM] oral disintegrating tablet (ODT) delivery platform. EasyTec (ODT) tablets disintegrate in approximately 10 to 30 seconds with only saliva and may assist in patient compliance. EasyTec (ODT) importantly also provides an opportunity for product life cycle planning and is patented in both the U.S. and Europe. Antares will receive funding for both feasability and development activities over the course of the contract. It is anticipated that the parties will enter into an exclusive licensing arrangement upon satisfactory evaluation.

Jack E. Stover, President and CEO of Antares Pharma, said, "This agreement represents an important milestone in potentially validating the utility of Antares' proprietary EasyTec (ODT) technology, as a component of life cycle planning for opiates."

About EasyTec[TM] Orally Disintegrating Tablet (ODT) Fast-Dissolve Technology

Antares Pharma's EasyTec[TM] is a simple, cost-efficient, and robust technology platform which uses direct compression during the tablet making process. EasyTec[TM] relies on the combination of classic disintegrants and a specific excipient to enhance rates of disintegration. All excipients are compendial, low cost, and do not involve special production or manufacturing equipment. EasyTec[TM] tablets satisfy pharmacopoeial requirements for hardness and friability when compared to conventional tablets, therefore conventional high-speed rotary tablet presses are used for tablet compression and there is no requirement for specialized packaging. The disintegration time is generally less than 10 seconds for EasyTec tablets with a mass lower than 200 mg increasing up to 30 seconds for tablets with a mass increasing to 1000 mg. EasyTec[TM] technology is compatible with a broad range of actives, with high or low drug loading, and can be used with traditional and specialized excipient categories in addition to the incorporation of taste-masking and flavouring technologies.

Antares Pharma

Antares Pharma is a specialized pharma product development company focused on developing patented drug delivery systems and injectable device engineering capabilities. Antares' current technology platforms include its ATD[TM] Advanced Transdermal Delivery system, and its related TecTix[TM] system for topical and transmucosal delivery, its Easy Tec[TM] oral fast-melt technology, and subcutaneous injection technology platforms including both Vibex[TM] disposable mini-needle injection device and Valeo[TM]/Vision[R] reusable needle-free injection devices. Antares Pharma is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new pharmaceutical products and injectable devices. Overall, Antares' product pipeline, if approved, will address unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience. Antares Pharma has corporate headquarters in Princeton Crossroads Corporate Center in Ewing, NJ, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Safe Harbor Statement

In addition to historical facts or statements or current conditions, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, including statements regarding the timing of product sales, market estimates and market potential. Forward-looking statements provide Antares' current expectation or forecasts of future events. Antares' results could differ materially from those reflected in these forward-looking statements due to decisions of regulatory authorities, Antares' ability to execute on its development plans and general financial, economic, regulatory and political conditions affecting the pharmaceutical industry generally. For a discussion of these and other risks and uncertainties that may effect the forward-looking statements, please see the risk factors in Antares' quarterly reports filed with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Antares undertakes no obligation to update publicly any forward-looking statement.